Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
Home3D Technology3D LifePrints Achieves ISO 13485:2016 Certification

3D LifePrints Achieves ISO 13485:2016 Certification

MARKET REPORTS

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets – ResearchAndMarkets.com

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts – ResearchAndMarkets.com

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

3D LifePrints, a leading 3D technology company providing innovative solutions to the medical sector, announced today that it has achieved ISO 13485:2016 certification for its Quality Management System (QMS).

3D LifePrints notes the certification enables 3D LifePrints to expand its industry-leading Point-of-Care model by launching a new range of patient-specific sterilizable Surgical Guides and Anatomical Models, whilst continuing to deliver its existing custom-made medical devices.

The certification is underpinned by 3D LifePrints’ Digital Platform EmbedmedTM. It includes the design and manufacture of sterilizable devices within a Controlled Environment in one of 3D LifePrints’ embedded Hubs.  This innovation brings the timeline for delivery of these types of devices down from weeks to days.

An internationally recognized standard of excellence, ISO 13485:2016 is a stringent set of guidelines for the medical device industry. The standard ensures that an organization maintains its quality and compliance levels specific to the design, manufacture, and distribution of medical devices.

Henry Pinchbeck, CEO says: “It has long been our goal to standardize our processes by adherence to this internationally recognized standard. The formal certification of our QMS opens up considerable market opportunities for the business and is a clear signal to our customers of the importance we attach to Quality Assurance and Patient Care.”

3D LifePrints’ primary focus is the supply of patient-specific 3D printed medical devices to organizations including hospitals, universities, and medical device manufacturers. Their current key Hubs include Alder Hey Children’s Hospital in Liverpool, Nuffield Orthopaedic Centre in Oxford, Wrightington Hospital in Greater Manchester, and Leeds General Infirmary.

The company operates a unique operating model where the products are delivered AA Service from embedded Hubs within host institutions. The Point-of-Care service includes bio-medical engineers; a range of advanced 3D printing hardware and a suite of software. The embedded nature enables the host institution to enjoy all of the benefits of having an ‘in-house’ service including ease of access to an engineer and immediate delivery of the devices.

spot_img

DON'T MISS

AMRA Medical’s Whole-body MRI Analysis Used in FSHD Clinical Trial Research Network Study for Biomarker Development

To date, the MOVE study has used functional tests as primary outcomes, but recent studies have shown the promise of MRI for FSHD.

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy